Program Overview
This content is derived from a CME symposium held in conjunction with the Advanced Curriculum for Multiple Sclerosis 2018 in San Diego, California. The five expert faculty will highlight individualized therapeutic strategies of switching and sequencing to improve outcomes for patients with multiple sclerosis (MS). Methods for predicating and monitoring disease therapy in the MS patient population will be reviewed. Recent clinical trial data will be analyzed and clinical relevance determined. The faculty will utilize an interactive panel format to debate optimal strategies for selecting and switching therapies in the MS landscape. This discussion-based CME program will provide clinicians with vital information for improving healthcare outcomes in patients with multiple sclerosis.
Target Audience
Neurologists and other healthcare professionals who care for patients with multiple sclerosis
Learning Objectives
- Discuss the available methods to predict and monitor disease worsening in patients with multiple sclerosis
- Review evidence-based data for the rationale of sequencing, switching, and/or escalating MS therapeutics
- Understand and apply the principles of personalized medicine into treatment strategies for the lifelong management of patients with multiple sclerosis
Faculty
Fred D. Lublin, MD
Saunders Family Professor of Neurology
Director, Corinne Goldsmith Dickinson Center for MS
Icahn School of Medicine at Mount Sinai
New York, New York
Giancarlo Comi, MD, PhD
Department of Neurology
Institute of Experimental Neurology
Vita-Salute San Raffaele University
Milan, Italy
Hans-Peter Hartung, MD, PhD
Department of Neurology and Centre of Neuropsychiatry
UKD and LVR Klinik
Heinrich-Heine University
Düsseldorf, Germany
Aaron Miller, MD
Professor of Neurology
Medical Director, Corinne Goldsmith Dickinson Center for MS
Icahn School of Medicine at Mount Sinai
New York, New York
Benjamin Segal, MD
Holtom-Garrett Family Professor of Neurology
Director, University of Michigan Multiple Sclerosis Center
Ann Arbor, Michigan
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
| Faculty | Relationship Identified With: |
| Fred D. Lublin, MD (Chair) | Consultant/Advisor: AbbVie Inc.; Acorda Therapeutics; Actelion Pharmaceuticals Ltd.; Apitope; Atara Biotherapeutics; Bayer HealthCare Pharmaceuticals; Biogen; Celgene Corporation; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd; Forward Pharma; Genentech, Inc.; Innate Immunotherapeutics; Mapi-Pharma Ltd.; MedDay Pharmaceuticals; MedImmune; Novartis AG; Polpharma; Receptos; Regeneron; Sanofi Genzyme; Teva Pharmaceutical Industries Ltd.; TG Therapeutics, Inc.; ToyomaGrant/Research Support: Actelion Pharmaceuticals Ltd.; NMSS; Novartis AG; Teva Pharmaceutical Industries Ltd.; Transparency Life SciencesSpeakers Bureau: Genentech, Inc.; Genzyme Corporation |
| Giancarlo Comi, MD, PhD | Consultant/Advisor: Almirall; Biogen; Celgene Corporation; F. Hoffmann-La Roche Ltd; Forward Pharma; MedDay Pharmaceuticals; Merck & Co.; Novartis AG; Receptos; Sanofi Genzyme; Teva Pharmaceutical Industries Ltd.. |
| Hans-Peter Hartung, MD, PhD | Consultant/Advisor: Biogen; F. Hoffmann-La Roche Ltd; GeNeuro; Genzyme Corporation; Novartis Pharmaceuticals Corporation; Opexa Therapeutics, Inc.; Receptos; Teva Pharmaceutical Industries Ltd. |
| Aaron Miller, MD | Consultant/Advisor: Accordant Health Services; Adamas Pharmaceuticals, Inc.; Biogen; Celgene Corporation; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Mallinckrodt Pharmaceuticals; Mapi-Pharma Ltd.; Novartis AG; Sanofi GenzymeGrant/Research Support: Biogen; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Mallinckrodt Pharmaceuticals; MedDay Pharmaceuticals; Novartis AG; Sanofi GenzymeSpeakers Bureau: Biogen; F. Hoffmann-La Roche Ltd; Genentech, Inc. |
| Benjamin Segal, MD | Grant/Research Support: Genentech, Inc.; Mallinckrodt Pharmaceuticals |
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Emma Boring, Nicole Brestowski and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AcademicCME is accredited as a provider of continuing nursing education by the American Nursing Credentialing Center’s Commission on Accreditation.
Credit Designation Statement
AcademicCME designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AcademicCME designates this enduring material for a maximum of 1.50 CNE contact hours.
Financial Support
This activity has been supported by an independent educational grant from Sanofi Genzyme.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Sanofi Genzyme do not recommend the use of any agent outside of the labeled indications.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
- All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
- Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
- 60 minutes of participation = 1 CNE contact hour
CE Inquiries/Special Needs
For all CME/CNE inquiries or special needs, please contact [email protected].
